AVALON VENTURES MANAGEMENT, LLC

CIK 2026666 · View on SEC EDGAR ↗

Portfolio value
$14.2M
#8,934 of 9,443 by 13F value · top 94.6%
Positions
2
As of
Sept. 30, 2025 Data as of Q3 2025

Portfolio value QoQ: -25.3% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
2
Effective number of positions
1.2

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q3 2025: 0.0% Est. buys $244,400 · sells $0

Median holding: 3.0 quarters Tracked Q4 2024–Q3 2025 · 100.0% still held

New positions
0
Increased
1
Decreased
0
Closed
0
On this page

Performance vs S&P 500

Tracked Q4 2024–Q3 2025
-32.9%
S&P 500 total return (same window)
+13.4%
Excess return
-46.3%

Annualized: -41.3% · S&P 500: +18.3%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Technology
90.8%
Healthcare
9.2%

Full portfolio 2 positions

Type Streak 8Q trend
KLTR Kaltura, Inc. - Common Stock $12,906,298 90.83% 8,962,707 $-5,108,743
JANX Janux Therapeutics, Inc. - Common Stock $1,302,652 9.17% 53,300 $302,422 Up ×1

Top movers (QoQ)

Security Action Shares Δ Value Δ
KLTR Price move only +0 -$5.1M
JANX Bought more +10K +$302K